Farah J M, Hall N R, Bishop J F, Goldstein A L, O'Donohue T L
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland.
J Neurosci Res. 1987;18(1):140-6. doi: 10.1002/jnr.490180121.
In addition to reconstituting immune competence, the thymus gland preparation, thymosin fraction 5 (TSN-5), has recently been shown to stimulate secretion of hormones from the hypothalamic-pituitary adrenal axis in vivo and from pituitary corticotropes in vitro. The purpose of the present study was to investigate the effects of TSN-5 on secretion of immunoreactive beta-endorphin (i beta-E) by mouse corticotropic tumor cells. The release of i beta-E by AtT-20 pituitary tumor cells was increased in a dose-dependent manner by concentrations of 30-600 micrograms/ml of TSN-5, whereas concentrations greater than 1,000 micrograms/ml were increasingly less effective in stimulating secretion. TSN-5 (600 micrograms/ml) significantly stimulated i beta-E release within 7 min; maximal secretory responses (up to 275% of control release) occurred by 4 hr. The secretory response of AtT-20 cells to 600 micrograms/ml TSN-5 (37.9 +/- 2.0 vs. 16.1 +/- 1.0 ng i beta-E/ml/4 hr, mean +/- SE) was similar in magnitude to release evoked by 0.1 microM corticotropin-releasing factor (CRF). Combining TSN-5 and CRF treatments increased secretion of i beta-E to nearly 600% of control levels, an effect greater than an additive influence of the two independent treatments. Whereas CRF treatment reduced the levels of i beta-E in AtT-20 cell extracts after 24-hr treatment by 45% (231.8 +/- 24.7 vs. 417.2 +/- 17.8 ng i beta-E/mg protein, CRF vs. vehicle treatments, respectively), TSN-5 did not significantly alter cellular hormone content. Neither TSN-alpha 1 nor TSN-beta 4, two of the component peptides of TSN-5, affected basal or CRF-stimulated release of i beta-E, indicating that an unidentified constituent(s) is corticotropic.(ABSTRACT TRUNCATED AT 250 WORDS)
除了重建免疫能力外,胸腺制剂胸腺素组分5(TSN - 5)最近已被证明在体内可刺激下丘脑 - 垂体 - 肾上腺轴分泌激素,在体外可刺激垂体促肾上腺皮质激素细胞分泌激素。本研究的目的是探讨TSN - 5对小鼠促肾上腺皮质肿瘤细胞分泌免疫反应性β - 内啡肽(iβ - E)的影响。30 - 600微克/毫升浓度的TSN - 5可使AtT - 20垂体肿瘤细胞释放iβ - E呈剂量依赖性增加,而浓度大于1000微克/毫升时刺激分泌的效果逐渐减弱。TSN - 5(600微克/毫升)在7分钟内显著刺激iβ - E释放;最大分泌反应(高达对照释放的275%)在4小时时出现。AtT - 20细胞对600微克/毫升TSN - 5的分泌反应(37.9±2.0对16.1±1.0纳克iβ - E/毫升/4小时,平均值±标准误)在幅度上与0.1微摩尔促肾上腺皮质激素释放因子(CRF)诱发的释放相似。联合使用TSN - 5和CRF处理可使iβ - E分泌增加至对照水平的近600%,这一效应大于两种独立处理的相加影响。虽然CRF处理24小时后可使AtT - 20细胞提取物中iβ - E水平降低45%(分别为231.8±24.7对417.2±17.8纳克iβ - E/毫克蛋白,CRF处理与溶剂处理),但TSN - 5并未显著改变细胞内激素含量。TSN - 5的两种组成肽TSN - α1和TSN - β4均不影响基础或CRF刺激的iβ - E释放,表明存在一种未鉴定的促肾上腺皮质成分。(摘要截断于250字)